Rocket Pharmaceuticals is a Buy, with strong catalysts, undervalued programs, and significant upside. Click here to read my analysis of RCKT stock.
Orpha Labs AG today announced its compassionate use program to make ORL–101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback